1) Merck, Parexel Reach Biosimilar Development Deal.
2) Sanofi-aventis Enters into Two Research & Development Collaborations with the University of California, San Francisco “….The first collaboration promotes innovative research in pharmacological science and in multiple therapeutic areas, such as oncology, aging, diabetes and inflammation. The second collaboration is an oncology partnership that will focus on project-based collaboration to accelerate the progression of research through the clinical proof of concept stage…”
3) Merck Patent medicine journal includes new entry (addendum C): Patent number is 221123 (exp: 15-Jul-2018); Medicine protected: Not identified (will be updated)
4) US litigations
(ii) Shire Canada Inc vs Alkem Laboratories Ltd (product: Lanthanum carbonate) patents in suit: 7,465,465 & 5,968,976; filed at District of Illinois on Jan 12, 2011 View on PriorSmart.
(iii) Allergan vs Sandoz (product: Tropsium chloride) patents in suit: 7,781,448; 7,781,449; 7,759,359; 7,763,635 & 7,410,978; filed at Delaware on Jan 12, 2011 View on PriorSmart.
(iv) Aventis Pharma S.A vs Sandoz Inc (product: Docetaxel) patents in suit: 5,714,512; filed at Delaware on Jan 12, 2011 View on PriorSmart.
(v) Bayer Schering Pharma AG vs Sun Pharma (product: Drospirenone; Ethinyl Estradiol) patents in suit: RE37564; RE37838 & RE38253; filed at District of Nevada on Jan 12, 2011 View on PriorSmart